Clean Science & Technology Ltd

- FY ’25 CAPEX: Rs. 215 crores invested in subsidiary Clean Fino-Chem. - FY ’26 CAPEX: Rs. 300 crores planned, primarily for two new performance chemical projects. - One product commercialization expected by August FY ’26. - Second product commercialization expected by February FY ’26. - Further CAPEX plans for FY ’27 will be announced around six months after these products come online. - No immediate CAPEX projects slated for FY ’27 as of now; future investments contingent on commercialization progress. - HALS capacity expansion (total capacity over 10,000 tons) ramp-up expected by FY ’28 before considering Phase-two expansion.

- Revenue potential is estimated between Rs. 2,500 crores to Rs. 3,000 crores, likely over the next three years. - Existing products are expected to grow at an industry rate of 5-6% annually. - New product launches, including performance chemicals and HALS, will drive significant growth and absorb overheads. - HALS sales target: from Rs. 80 crores in FY '25 to Rs. 210 crores in FY '26 and ramping up fully by FY '27-’28 with total capacity over 10,000 tons. - Performance chemicals (two new products) to commercialize in FY '26; revenue contribution expected mostly from FY '27 onward. - MEHQ volumes anticipated to grow 4%-5% year-on-year. - Domestic market share expansion possible, e.g., up to 65% in HALS segment. - EBITDA margins targeted around 40% at consolidated level by FY '26-’27.

- There is no specific mention of any new fundraising through debt or equity in the transcript. - The company has undertaken significant CAPEX totaling Rs. 300 crores for FY '25 and FY '26 focused on two new performance chemical products. - For FY '27, CAPEX plans will be announced after the commercialization and ramp-up of these new products. - No mention of debt or equity issuance was made during the call. - The company maintains a strong cash balance of Rs. 400 crores despite increased CAPEX and higher dividend payout. - The focus appears to be on internal cash generation and operational growth rather than immediate external fundraising.

- Revenue potential is expected to be Rs. 2,500 to Rs. 3,000 crores within the next three years. - EBITDA margins are targeted to be maintained around 40% at the consolidated level, driven by a mix of HALS, pharma intermediates, and performance chemicals. - HALS segment revenue is projected to grow from Rs. 80 crores in FY ’25 to Rs. 210 crores in FY ’26, with a full ramp-up expected around FY ’27–’28. - Industry-standard growth rates of 4%-5% are expected for products like MEHQ, TBHQ, and BHA. - Operating profit growth at the consolidated level is anticipated to be in the range of 18%-20% in FY ’26, supported by volume growth and new product launches that will absorb overhead costs. - New performance chemical products and pharma intermediates will provide margin accretive growth as they scale up. - HALS volumes are expected to grow significantly from 600 tons in FY ’24 to 4,500 tons in FY ’26.

The transcript does not explicitly state the current or expected order book or pending orders for Clean Science and Technology Limited. However, some relevant points that indirectly reflect demand and growth expectations include: - HALS sales volume grew significantly from 600 tons in FY '24 to approximately 2,000 tons in FY '25. - Target for HALS sales in FY '26 is 4,500 tons, with full capacity expansion planned by FY '28 (total capacity: 10,000 tons). - Successful validation by key customers in Middle East, Southeast Asia, and Europe indicates strong sales momentum. - The company expects revenue potential of Rs. 2,500 to Rs. 3,000 crores in the next three years. - Margins are expected to be maintained around 40% EBITDA on a consolidated basis. - CAPEX of Rs. 300 crores planned for current year to support new product commercializations. - Volume growth seen in existing products like MEHQ and BHA with capacity utilization around 70-72%, indicating scope for volume increase. No direct order book or pending orders data provided in the transcript.